葡萄糖通过SIRT1调节质瘤中的HMGB1信号通路
Yu Wang1, Shuai Wang1, Yuhao Wang1
1Department of Neurosurgery, The Affiliated Chuzhou Hospital of Anhui Medical University, The First People's Hospital of Chuzhou, Chuzhou 239000, China.
Cellular signalling
|March 11, 2024
概括
高血糖水平通过降低SIRT1的调节促进质瘤的进展,从而增加HMGB1的乙化和信号. 这会影响瘤恶性和患者的预后.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 葡萄糖对癌症至关重要,但其在质瘤调节中的作用尚不清楚.
- SIRT1 (一种脱乙酶调节剂) 与恶性瘤进展有关.
- 了解葡萄糖和SIRT1相互作用对于质瘤研究至关重要.
研究的目的:
- 研究葡萄糖和SIRT1在质瘤中的作用.
- 检查与质瘤临床病理特征和预后有关的SIRT1表达.
- 阐明在质瘤中将葡萄糖,SIRT1和HMGB1连接在一起的分子机制.
主要方法:
- 利用TCGA数据库对质瘤患者的SIRT1表达分析.
- 采用西式斑点检测,检测质瘤细胞中的SIRT1蛋白水平.
- 评估了不同葡萄糖度对质瘤细胞功能和SIRT1/HMGB1通路的影响.
- 通过SRT1720.20进行了弹性实验.
主要成果:
- SIRT1是一种瘤抑制基因,在质瘤中表达低,与预后不佳相关.
- 高度的葡萄糖增加了质瘤细胞的增殖,迁移和入侵,同时抑制了亡.
- 葡萄糖降低SIRT1的表达,增加乙化HMGB1,促进HMGB1的信号传递,并驱动质瘤恶性.
结论:
- 葡萄糖通过SIRT1.1.通过调节HMGB1信号通路来促进质瘤的进展.
- 这种监管机制突出了质瘤治疗干预的重要途径.
- 这项研究提供了对葡萄糖代谢及其对质瘤发病因子的影响的关键见解.
相关概念视频
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:15Hypoglycemia and Glucagon
260
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
260
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
01:27Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K